Important Progress in Treatment of Early and Late Stage Breast Cancer With
Herceptin, Avastin and T-DM1
- Roche to Present new Results That Could Offer a Better Future to
Women With Early and Very Advanced Breast Cancer, at the CTRC-AACR
San Antonio Breast Cancer Symposium
"Breast cancer is the most common cancer among women worldwide with more than one million new cases diagnosed every year and nearly 400,000 deaths, so it is vital that we continue to provide more treatment options," said William M. Burns, CEO of Roche Pharma. "The much anticipated data on Herceptin, Avastin and the investigational drug T-DM1 will be welcomed by physicians treating women with early and very advanced stages of breast cancer as it will offer them more choices for fighting this devastating disease."
Two Herceptin studies in early breast cancer, five year follow up data (N9831, BCIRG 006)
- 5-years of follow-up data will be presented from these pivotal phase
III studies that have already shown efficacy in patients when adding
12 months of Herceptin to standard therapy.
- Both studies were seeking to answer questions the medical community
has been contemplating regarding the best way of giving their
patients Herceptin treatment.
Avastin RIBBON-2 study, second-line treatment data
- Avastin is well established as a first-line treatment for women with
advanced breast cancer. RIBBON-2 will report on the benefits of
Avastin in combination with commonly used chemotherapies in the
second-line setting where currently the only option is subsequent
chemotherapy.
T-DM1 4374 study in very advanced breast cancer
New data from a phase II study (TDM4374) in a very advanced patient population who have exhausted other treatment options will be presented. This follows on from another phase II study (TDM4258) that was presented at ASCO 2009 which showed encouraging results in women with advanced HER2-positive breast cancer.
In addition, further data from the phase II study BO17929 will be presented, demonstrating that the combination of pertuzumab and trastuzumab shows efficacy in patients with HER2-positive advanced breast cancer whose disease had progressed during prior treatment with Herceptin plus chemotherapy.(i) The data, which suggest that combining pertuzumab and trastuzumab may offer an effective new treatment option to patients with HER2-positive advanced breast cancer, have been accepted as a poster presentation on Saturday 12 Dec, 17:30 - 19:30, Poster Session 5, Exhibit Halls A-B.
Details of key studies being presented:
Herceptin N9831 study
The study is part of the official SABCS press programme on Saturday
12 Dec., 08:00 hrs.
Dr E. Perez, Results of chemotherapy alone, with Oral
et al sequential or concurrent addition of presentation
trastuzumab in the NCCTG N9831 Saturday 12
HER2-positive adjuvant breast cancer Dec, 15:00,
trial. General
Session 6,
Exhibit Hall
D.
Herceptin BCIRG 006 study
Dr. D. Slamon, Phase III randomized trial comparing Oral
et al doxorubicin and cyclophosphamide followed presentation
by docetaxel (AC à T) with doxorubicin and Saturday 12
cyclophosphamide followed by docetaxel and Dec, 09:45,
trastuzumab (AC à TH) with docetaxel, General
carboplatin and trastuzumab (TCH) in Session 5,
Her2neu positive early breast cancer Exhibit Hall
patients: BCIRG 006 study. D.
Avastin RIBBON-2 study
The study is part of the official SABCS press programme on Friday
11 Dec., 12:30 hrs.
Dr. A. RIBBON-2: A randomized, double-blind, Oral
Brufsky, et al placebo-controlled, phase III trial presentation
evaluating the efficacy and safety of Friday 11
bevacizumab in combination with Dec, 15:00,
chemotherapy for second-line treatment of General
HER2-negative metastatic breast cancer. Session 4,
Exhibit Hall
D.
T-DM1 4374 study
Dr. I. Krop, A phase II study of trastuzumab-DM1 Poster
et al (T-DM1), a novel HER2 antibody-drug presentation
conjugate, in patients previously treated Saturday 12
with lapatinib, trastuzumab, and Dec, 07:00 -
chemotherapy. 09:00.
Poster
Discussion
7, Ballroom
B.
The above mentioned studies and data represent the latest results of clinical research for each treatment and are not necessarily part of the indicated licence in each country. For detailed label information, visit the website of your health authority or the EMEA website http://www.emea.europa.eu/
In HER2-positive breast cancer, increased quantities of the HER2 protein are present on the surface of the tumour cells. This is known as 'HER2-positivity'. High levels of HER2 are present in a particularly aggressive form of the disease which responds poorly to chemotherapy. Research shows that HER2-positivity affects approximately 20-30 percent of women with breast cancer.(ii)
The 2009 CTRC-AACR
About Roche
Headquartered in
In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D.
The Group posted sales of 45.6 billion Swiss francs. Genentech,
All trademarks used or mentioned in this release are protected by law.
Additional information
- Roche SABCS materials:
http://www.roche.com/media/events/med-sabcs2009.htm
- More about Roche's work in oncology:
http://www.roche.com/media_backgrounder/media_oncology.htm
- Oncology backgrounders:
http://www.roche.com/media_backgrounder/media_oncology.htm
- Roche.com section on PHC:
http://www.roche.com/research_and_development/phc_in_r_d.htm
- http://www.thenewsmarket.com
- Video clips and backgrounder on products:
http://www.roche.com/med-cor-2009-05-15.htm
References
----------
(i) Baselga J. et al., Abstract 1004. American Society of Clinical
Oncology Annual Meeting 2007.
(ii) Harries M, Smith I. The development and clinical use of trastuzumab
(Herceptin). Endocr Relat Cancer 9: 75-85, 2002.
For further information: Roche Group Media Relations: Phone: +41-61-688-8888, e-mail: [email protected], Daniel Piller (Head), Alexander Klauser, Martina Rupp, Claudia Schmitt, Nina Schwab-Hautzinger
Share this article